Drug Trial Radar · NCT00390585
Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
Last checked: Nov 19, 2026Latest source record: Mar 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
324
Actual
Start
Jul 2006
Primary completion
Jan 2008
Study completion Dec 2008
Sponsor
- Lead sponsor
- Deutsches Herzzentrum MuenchenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that Iodixanol 320 is associated with a lower incidence of contrast-induced nephropathy (CIN) when compared with hyperosmolar contrast medium Iomeprol 350 in patients with impaired renal function undergoing percutaneous coronary interventions (PCI).
Conditions
- Renal Insufficiency, Chronic
- Angioplasty, Transluminal, Percutaneous Coronary
- Coronary Arteriosclerosis
Interventions
Iodixanol 320Drug
Iodixanol 320 is used as contrast media while coronary intervention.
Iomeprol 350Drug
Iomeprol 350 is used as contrast media while coronary intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Contrast-induced nephropathy after percutaneous coronary intervention during primary hospitalizationTime frame: primary hospitalization
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
1. Medizinische Klinik, Klinikum rechts der Isar
München, Germany
Deutsches Herzzentrum Muenchen
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.